The original targeted intraoperative radiotherapy (TARGIT) for breast cancer using Intrabeam by Jayant S Vaidya in 2001 used in the TARGIT-A trial.
Developed in collaboration with industry; INTRABEAM manufactured by Carl Zeiss.
See http://www.ucl.ac.uk/~rmhkjsv/papers/targit.htm#disclaimer http://www.targit.org.uk
Updates
A few updates about the TARGIT technique using Intrabeam:
1. The shield on the posterior wall of the tumour bed is no longer used.
2. The posterior excision need not extend up to the pectoral fascia if adequate margin can be achieved without such an excision.
3. The transparent sterile cover for the Intrabeam is now available from the manufacturers.
A few additional points that should be noted:
1. Conceptually, the fresh undisturbed tumour bed - the the empty, nearly spherical shell of normal breast tissue that surrounds the excised specimen - needs to be neatly in contact with the sphere of the Intrabeam applicator. NB the conical shaft of the applicator does no
7
12/3/2021
New Insights from the TARGIT-A trial of radiotherapy during lumpectomy for breast cancer
14
12/1/2021
Invited talk at the Association of Breast Surgeons of India Conference, 26 Nov 2021
15
12/1/2021
TARGIT-IORT for breast cancer NCRI conference Nov 2021 - 5-Min Short talk
13
12/1/2021
Invited talk at the NHS Oncology Conference 23 Nov 2021
16
12/1/2021
Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT.
Nathan J Coombs, Joel M Coombs, Uma J Vaidya, Julian Singer, Max Bulsara, Jeffrey S Tobias, Frederik Wenz, David J Joseph, Douglas A Brown, Richard Rainsbury, Tim Davidson, Douglas J A Adamson, Samuele Massarut, David Morgan, Ingrid Potyka, Tammy Corica, Mary Falzon, Norman Williams, Michael Baum, Jayant S Vaidya
BMJ Open 2016;6:e010703. http://bmjopen.bmj.com/content/6/5/e010703.full
http://blogs.bmj.com/bmjopen/2016/05/09/radiotherapy-during-surgery-could-save-millions-of-travel-miles-and-tonnes-of-co2/
The use of TARGIT intraoperative radiotherapy for eligible patients with breast cancer
significantly reduces their journeys for treatment and has environmental benefits: 5 million miles of travel, 170 000 woman-hours and 1200 tonnes of CO2 (a forest of 100 hectares) per year in the UK
48
11/24/2018
Rethinking Neoadjuvant Chemotherapy for breast cancer- Prof Jayant Vaidya
Original BMJ paper is available at https://www.bmj.com/content/360/bmj.j...
Full paper is available at http://discovery.ucl.ac.uk/10041365/
Full paper + Discussion is available at http://bit.ly/nactbmj2018full
The BMJ Podcast https://soundcloud.com/bmjpodcasts/ne...
Key messages
Neoadjuvant chemotherapy is being increasingly used for breast cancer despite higher rates of local recurrence and no evidence of survival benefit, mainly because of the immediate and dramatic pathological responses seen with newer drugs
The increased pathological response of the primary tumour in the breast does not translate into a survival benefit even when given in the adjuvant setting, challenging the paradigm of “window of opportunity” studies
We must acknowledge that neoadjuvant chemotherapy may not be beneficial to breast cancer patients
We should consider reducing the widespread use of neoadjuvant chemotherapy
35
11/23/2018
The Royal Society - Experts and patients discussing TARGIT IORT for breast cancer, 31 October 2018
http://www.targit.org.uk
72
11/20/2018